Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

l trial for elagolix, the  most advanced clinical program in the Company's pipeline, will fail to support the additional Phase III clinical trial required for regulatory approval; risk that the elagolix Phase III program overall will encounter delays for regulatory or other reasons; risk that the elagolix Phase III clinical program will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis or support filings for regulatory approval; risk that the uterine fibroid elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; and  risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's repor
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... South San Francisco, CA (PRWEB) March 25, 2015 ... Trial Provide Support for Novel Mechanism of Action ... CA, March 25, 2015 – Cytokinetics, Incorporated (Nasdaq: ... to its fast skeletal muscle troponin activator tirasemtiv ... results from a Phase IIa “Evidence of Effect” ...
(Date:3/25/2015)...  The Technology Association of Georgia ... promotion and economic advancement of Georgia,s ... of its Top 40 Innovative Technology Companies in ... group at the 2015 Georgia Technology Summit (GTS) on ... TAG,S Top 40 Awards recognize Georgia ...
(Date:3/25/2015)... Proove Biosciences , a commercial ... announce the success of their commercially supported symposium, ... Optimize the Management of Pain, at the 31st Annual ... Maryland on Thursday, March 19th, 2015. , ... Lynn Webster , M.D., former Florida Society of ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 ... segmented on the basis of products, technology, ... in this report are radar, laser, infra-red, ... encompassing video guidance systems, terrain mapping systems, ... market data Tables and 60 Figures spread ...
Breaking Biology Technology:Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 2Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 4Proove Biosciences Hosts Symposium on Incorporating Genetic Testing to Optimize the Management of Pain 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 3
... May 25 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: BSPM ... Hepatitis B medicine,Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), and a ... assembly of its production line for its proprietary Zushima product. , ... ...
... NEW YORK , May 25, 2010 ... biosensor and microprocessor technologies for use in,portable monitoring devices, ... the overall daily activity level of an individual and ... overweight or obese. The bracelet,designed both for children and ...
... May 25, 2010 t2cure GmbH, a biopharmaceutical,company developing and marketing ... t2c001 has been,certified by the European Medicines Agency (EMA). , ... t2c001 is the ... Therapy Medicinal Products (ATMPs). It is a somatic,cell therapy product derived from ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 2Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 4SPO Medical Announces Innovative Wellness Bracelet 2SPO Medical Announces Innovative Wellness Bracelet 3SPO Medical Announces Innovative Wellness Bracelet 4SPO Medical Announces Innovative Wellness Bracelet 5t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA 2t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA 3t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA 4
(Date:3/18/2015)... March 18, 2015 As mobile payments ... revolutionary smart wallets and apps continue to be introduced into ... in the mobile payment industry in focus today are:  NXT-ID, ... (NYSE: BABA ), Apple Inc. (NASDAQ: ... Facebook Inc. (NASDAQ: FB ) NXT-ID, ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... the parareptiles, a diverse group of bizarre-looking terrestrial vertebrates ... small, slender, agile and lizard-like creatures, while others attained ... and bony spikes on their skulls. The researchers ... by the end-Permian extinction than at any other point ...
... years ago, the understory of late Mesozoic forests was dominated ... Today, only one genus from this group, Equisetum ... a prime candidate for being the oldest extant genus of ... the evolutionary beginnings of the genus Equisetum . Molecular ...
... (SALT LAKE CITY) New findings from University of Utah School of ... in the blood of patients who have chronic fatigue syndrome (CFS). ... study that linked CFS to XMRV. The study, performed by ... Singh, M.D., Ph.D., associate professor of pathology, was published May 4, ...
Cached Biology News:Reptile 'cousins' shed new light on end-Permian extinction 2Newly discovered plant fossil reveals more than age 2Newly discovered plant fossil reveals more than age 3Newly discovered plant fossil reveals more than age 4Comprehensive study finds no link between XMRV retrovirus and chronic fatigue syndrome 2Comprehensive study finds no link between XMRV retrovirus and chronic fatigue syndrome 3
... The IHC Select Immunoperoxidase Secondary Detection ... rat or goat IgG in the Primary ... antigens present in the specimen. Any excess ... Secondary Antibody Reagent (conjugated to biotin) is ...
... long double stranded RNA (dsRNA) has been ... diverse group of organisms as well as ... to the inhibition of protein expression by ... messenger RNA (mRNA). Attempts to induce RNA ...
... The TSQ Quantum Ultra defines a ... and environmental analysis. It features the ... probes, a titanium skimmer with superior skimming ... sensitivity. Its redesigned ion transfer tube ...
... a tetramethylrhodamine-conjugated jetSI-ENDO (excitation at ... nm), the powerful siRNA transfection ... to determine the transfection efficiency ... and trafficking of siRNAs. More ...
Biology Products: